Atea Pharmaceuticals, Inc. Stock Price, News & Analysis

Atea Pharmaceuticals announced new data showcasing the potent antiviral activity of AT-527 against SARS-CoV-2, highlighting its potential in treating COVID-19. The research indicates that AT-527, an orally administered agent, effectively inhibits viral replication in respiratory tissues, with a half-life of approximately 40 hours. Current clinical trials are studying a twice-daily regimen of 550 mg AT-527. These findings emphasize AT-527's capacity to minimize disease progression, highlighting its importance in both pre- and post-exposure treatment strategies.

Atea Pharmaceuticals (Nasdaq: AVIR) has commenced a Phase 2 clinical trial for AT-527, an oral antiviral treatment for patients with mild to moderate COVID-19. The trial, conducted in collaboration with Roche, aims to evaluate the drug's virological efficacy, safety, and pharmacokinetics, enrolling up to 220 patients across the UK, Ireland, and other countries. Primary outcomes will measure changes in SARS-CoV-2 virus RNA levels. AT-527 has shown promise in inhibiting viral replication in vitro, and the study aims to support the development of effective outpatient treatment options.

Atea Pharmaceuticals has appointed Jayanthi Wolf as Senior Vice President of Regulatory Affairs and Jonae Barnes as Senior Vice President of Investor Relations and Corporate Communications. These appointments are aimed at strengthening the company’s leadership in regulatory matters and communications as it advances its product candidates, including the Phase 3 program for AT-527 targeting COVID-19 and AT-752 for Dengue fever. Wolf has extensive experience from Merck, while Barnes brings over 20 years from various biotechnology firms.

BOSTON, Dec. 21, 2020 – Atea Pharmaceuticals (Nasdaq: AVIR) announces that CEO Jean-Pierre Sommadossi will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 9:10 a.m. ET. A live webcast will be available on the company’s website, with a replay for 90 days thereafter.

Atea focuses on developing antiviral therapeutics for severe viral infections including COVID-19, dengue, HCV, and RSV, utilizing a proprietary purine nucleotide prodrug platform.

Atea Pharmaceuticals (Nasdaq: AVIR) has been added to the Russell 2000 Index, effective December 21, 2020. This inclusion is part of the index's quarterly IPO additions and is expected to broaden the company's investor base and increase awareness of its antiviral therapies, especially AT-527 for COVID-19 treatment. The Russell indexes, benchmarked by around $9 trillion in assets, are crucial for investment managers and institutional investors.

Atea Pharmaceuticals (Nasdaq: AVIR) announced management's participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 12:35 p.m. ET. A live webcast will be available on their website, with a replay accessible for 90 days afterward.

Specializing in antiviral therapeutics, Atea focuses on developing treatments for severe viral infections, including COVID-19, hepatitis C, dengue, and RSV, leveraging their proprietary nucleotide and nucleoside prodrug platform.

Atea Pharmaceuticals has appointed Barbara Duncan to its Board of Directors, where she will also serve as Chair of the Audit Committee. Duncan brings extensive financial and public company expertise, having held senior roles at various biopharmaceutical firms, including Chief Financial Officer at Intercept Pharmaceuticals. Her appointment comes at a crucial time as Atea transitions to a publicly traded company and aims to advance its antiviral pipeline, particularly the oral COVID-19 treatment, AT-527. This strategic leadership change is expected to enhance Atea's market navigation and therapeutic development efforts.

Atea Pharmaceuticals (Nasdaq: AVIR) announced the closure of its initial public offering, raising a total of $345 million by selling 14,375,000 shares at $24.00 each. This includes the complete exercise of the underwriters' overallotment option, adding an additional $45 million. The stock began trading on the Nasdaq Global Select Market on October 30, 2020. Major underwriters included J.P. Morgan and Morgan Stanley.

Atea Pharmaceuticals has priced its initial public offering at $24.00 per share, offering 12,500,000 shares to the public, expected to generate $300 million in gross proceeds. The common stock will begin trading on Nasdaq under the ticker symbol AVIR on October 30, 2020, with the closing of the offering anticipated on November 3, 2020. The underwriters have a 30-day option to purchase an additional 1,875,000 shares. J.P. Morgan, Morgan Stanley, Evercore, and William Blair are the joint book-running managers.